,1200

## CERTIFICATE OF MAILING

by certify that this correspondence is being deposited with the United States Postal Service as first class mail in an elope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

ELI LILLY AND COMPANY

By Sinda M. Dunbin

Date Stune 14, 2001

PATENT APPLICATION

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re United States Patent No. 4,690,951

Patentees : David B. Anderson, et al.

Assignee : Eli Lilly and Company

Issue Date : September 1, 1987

Our Docket No.: X-5683B

06/811059

## STATUS LETTER

Assistants Commissioner for Patents Washington, D. C. 20231 Sir:

Applicant in this application filed a "Request for Extension of Patent Term Under 35 U.S.C. 156" on February 18, 2000. On April 20, 2000, Applicant received a copy of a letter dated April 4, 2000, from Ms. Karin Tyson of the U.S.P.T.O. to Mr. David Read of the Food and Drug Administration requesting information on PAYLEAN® (ractopamine hydrochloride). Applicant has received no further communication from the Patent and Trademark Office, or the FDA, regarding this application. It would be appreciated if the Office would advise Applicant of the current status of this application.

Respectfully submitted,

John C. Demeter

Attorney for Applicant Registration No. 30,167

Phone: 317-276-3785

Eli Lilly and Company Patent Division/JCD Lilly Corporate Center Indianapolis, Indiana 46285

Jone 13,2001